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Abstract
Both the endocannabinoid and noradrenergic systems have been implicated in neuropsychiatric disorders. Importantly, low levels of
norepinephrine are seen in patients with depression, and antagonism of the cannabinoid receptor type 1 (CB1R) is able to induce
depressive symptoms in rodents and humans. Whether the interaction between the two systems is important for the regulation of
these behaviors is not known. In the present study, adult male Sprague–Dawley rats were acutely or chronically administered the
CB1R synthetic agonist WIN 55,212-2, and a2A and b1 adrenergic receptors (AR) were quantified by Western blot. These AR have
been shown to be altered in a number of psychiatric disorders and following antidepressant treatment. CB1R agonist treatment
induced a differential decrease in a2A- and b1-ARs in the nucleus accumbens (Acb). Moreover, to assess long-lasting changes
induced by CB1R activation, some of the chronically treated rats were killed 7 days following the last injection. This revealed a
persistent effect on a2A-AR levels. Furthermore, the localization of CB1R with respect to noradrenergic profiles was assessed in the
Acb and in the nucleus of the solitary tract (NTS). Our results show a significant topographic distribution of CB1R and dopamine beta
hydroxylase immunoreactivities (ir) in the Acb, with higher co-localization observed in the NTS. In the Acb, CB1R-ir was found in
terminals forming either symmetric or asymmetric synapses. These results suggest that cannabinoids may modulate noradrenergic
signaling in the Acb, directly by acting on noradrenergic neurons in the NTS or indirectly by modulating inhibitory and excitatory input
in the Acb.
Introduction
The cannabinoid receptor type 1 (CB1R) can be found in several areas
of the brain such as the frontal cortex, basal ganglia, hippocampus,
amygdala and brainstem (Mackie, 2005), and it has been implicated in
the regulation of learning and memory as well as in depression,
anxiety and pain. CB1R activation is known to inhibit GABA and
glutamate release in several brain regions, including the hippocampus,
dorsal striatum, cerebellum and nucleus accumbens (Acb; Hoffman &
Lupica, 2000; Daniel & Crepel, 2001; Gerdeman & Lovinger, 2001;
Robbe et al., 2001). In addition to the effects of cannabinoids on
GABA and glutamate transmission, growing evidence points to a
significant role for monoamines in cannabinoid-induced behaviors.
Previous studies have shown important interactions between the
cannabinoid and noradrenergic systems (Oropeza et al., 2005, 2007;
Page et al., 2007; Fox et al., 2009; Jelsing et al., 2009). Systemic
administration of the synthetic cannabinoid agonist WIN 55,212-2
was shown to increase the release of norepinephrine (NE) in the
prefrontal cortex (PFC) (Oropeza et al., 2005). In addition,
WIN 55,212-2 increased c-fos expression in the locus coeruleus
(LC) and in the nucleus of the solitary tract (NTS; Oropeza et al.,
2005; Jelsing et al., 2009). Efferents of the LC and the NTS account
for most of the noradrenergic projections to the forebrain. The
noradrenergic input to cortical and limbic structures is important for
brain arousal, memory and mood (Aston-Jones et al., 1991; Heninger
et al., 1996). Dysregulation of this system plays a role in the
pathophysiology of depression (Heninger et al., 1996; Anand &
Charney, 2000; Nutt, 2002). Noradrenergic deficiency and dysfunction
of adrenergic receptors (AR) may be present in some patients with
depression and may be important for the response to antidepressants
(Anand & Charney, 2000). Consistent with this, various studies show
an increase in a2-AR density in brains of depressed suicide victims
(Meana et al., 1992; De Paermentier et al., 1997; Callado et al., 1998)
while b1-AR density is decreased (De Paermentier et al., 1990). With
regard to antidepressant treatment, the levels of a2- and b1-ARs have
been shown to decrease (De Paermentier et al., 1991, 1997) in areas
such as temporal cortex, amygdala and thalamus of antidepressant-
treated suicides. Moreover, chronic administration of WIN 55,212-2
has been shown to desensitize a2-ARs in noradrenergic-enriched areas
(Moranta et al., 2009). Elucidating the effects of cannabinoid
administration on the expression of these ARs may contribute to
Correspondence: A. F. Carvalho, 1Neurosurgery, as above.
E-mail: arfranky@gmail.com
Received 21 July 2009, revised 30 October 2009, accepted 10 November 2009
European Journal of Neuroscience, Vol. 31, pp. 286–301, 2010 doi:10.1111/j.1460-9568.2009.07054.x
ª The Authors (2010). Journal Compilation ª Federation of European Neuroscience Societies and Blackwell Publishing Ltd
European Journal of Neuroscience
identifying the mechanism by which cannabinoids are involved in
mood-related disorders (Hill & Gorzalka, 2005a; Witkin et al., 2005;
Leweke & Koethe, 2008).
In the present study, we studied the impact of a cannabinoid agonist
on limbic forebrain noradrenergic circuitry using biochemical and
neuroanatomical approaches. The limbic region analyzed, the Acb, is a
brain region involved in the integration of motivation-related infor-
mation, with important implications for drug addiction and mood
disorders (Di Chiara, 2002; Shirayama & Chaki, 2006). Understanding
how cannabinoids may impact noradrenergic input to the Acb may
provide important information regarding the effects of CB1R
compounds on drug-induced behaviors.
Materials and methods
Subjects
Adult male Sprague–Dawley rats (Harlan Laboratories, Indianapolis,
IN, USA) weighing 220–250 g were housed two or three per cage in a
controlled environment (12-h light schedule, temperature at 20C).
Food and water were provided ad libitum. The care and use of animals
were approved by the Institutional Animal Care and Use Committee
(IACUC) of Thomas Jefferson University and were conducted in
accordance with the NIH Guide for the care and use of laboratory
animals. All efforts were made to reduce the number of animals used.
Antibody characterization and specificity
A list with the characterization of all the primary antibodies used can
be found in Table 1. An affinity-purified polyclonal antibody directed
against the CB1R was used; it was generated against a fusion protein
containing the last 15 amino acids of the C-terminal of the rat CB1R
fused to glutathione S-transferase. The specificity of this CB1R
antibody has been determined in somatosensory cortex of mice
lacking CB1R by Bodor et al. (2005). In addition to the aforemen-
tioned study, additional controls were conducted here. For example,
immunoperoxidase detection of the CB1R antibody was conducted in
tissue sections obtained from the forebrain of mice deficient in the
CB1R (provided by Kenneth Mackie) and compared to that of similar
sections obtained from wild-type mice. In these experiments, perox-
idase detection for CB1R was absent in knockout tissue but present in
wild-type samples (Fig. 1). In addition, specificity controls involved
controlling for the secondary antibody by processing tissue that lacked
primary antibody incubation. In such experiments, run in parallel,
peroxidase immunoreactivity or immunogold–silver particles were not
detected in tissue sections from which the primary antibody had been
omitted (Supporting information, Fig. S1). To evaluate possible cross-
reactivity of secondary antibodies with the primary antisera in the dual
labeling experiments, some sections were processed for dual labeling
with omission of one of the primary antisera.
The monoclonal antibody against dopamine beta hydroxylase
(DBH) was raised against purified bovine DBH. The specificity of
the DBH antibody has also been demonstrated previously in our
laboratory (Oropeza et al., 2007). More specifically, preabsorption
with the respective antigen (Alpha Diagnostics, San Antonio, TX,
USA) resulted in an absence of immunolabeling in tissue sections
from the frontal cortex.
The monoclonal (clone CL-300) antibody directed against calbindin
was generated using purified calbindin-D from chicken gut. This
antibody revealed the same distribution in the Acb as described by
others (Voorn et al., 1989; Jongen-Relo et al., 1994).
The monoclonal antibody direct against the NE transporter (NET)
was generated using a peptide (amino acids 05–17) of the mouse
and rat NET coupled to keyhole limpet hemocyanin by the addition of
a C-terminal cysteine. To test the specificity of the NET antibody,
preabsorption of the antibody with the blocking peptide (1 lg ⁄ mL;
MabTechnologies, Stone Mountain, GA, USA) resulted in the absence
of immunolabeling in rat tissues containing the Acb (supporting
Fig. S2).
The polyclonal antibody against the a2A-AR was developed against
a synthetic peptide (Arg-Ile-Tyr-Gln-Ile-Ala-Lys-Arg-Arg-Thr-Arg-
Val-Pro-Pro-Ser-Arg-Arg-Gly) derived from amino acids 218–235 of
human, mouse, rat and pig a2A-AR. The polyclonal antibody against
the b1-AR was raised against a synthetic peptide (His-Gly-Asp-Arg-
Pro-Arg-Ala-Ser-Gly-Cys-Leu-Ala-Arg-Ala-Gly) derived from amino
acids 394–408 of mouse and rat b1-AR. The specificity of a2A- and
b1-AR antibodies was determined by preabsorption of the antibodies
with the respective blocking peptide (10 lg ⁄ mL; Sigma-Aldrich,
St Louis, MO, USA); this resulted in the absence of labeling in the
blots loaded with whole-brain protein samples (supporting Fig. S3).
The monoclonal antibody against microtubule-associated protein
(MAP2) was raised in mouse against rat brain MAP. The specificity of
the MAP2 antibody has been described (Teng et al., 2001), who found
no detectable band in Western blots from brain extracts of MAP2-
deficient mice.
Drug administration and Western blot analysis
WIN 55,212-2 (Sigma-Aldrich) was dissolved in 5% dimethyl
sulfoxide (DMSO; Fisher Scientific, Fair Lawn, NJ, USA) in 0.9%
saline and injected intraperitoneally in a volume of 1 mL ⁄ kg body
weight. A dose–response study was performed in which animals
Table 1. Characterization of the primary antibodies
Antigen Immunogen Manufacturer Host, mono ⁄ polyclonal Catalog no. Dilution
CB1R Last 15 aa of the C-terminal of the rat CB1R Dr K. Mackie* Rabbit polyclonal – 1:500
1:1000
DBH Purified bovine DBH Chemicon, Millipore Mouse monoclonal MAB308 1:1000
Calbindin D-28 Purified calbindin D-28 from chicken gut Abcam Mouse monoclonal ab9481 1:300
NET Peptide, aa 5–17 of mouse and rat NET MabTechnologies Mouse monoclonal NET05-1 1:1000
a2A-AR Synthetic peptide, aa 218–235 of human,
mouse, rat and pig
Sigma-Aldrich Rabbit polyclonal A-271 1:500
b1-AR Synthetic peptide, aa 394–408 of mouse and rat Sigma-Aldrich Rabbit polyclonal A-272 1:1000
MAP2 Rat brain MAP Abcam Mouse monoclonal ab11267 1:1000
*Synthesized in the laboratory of Dr K. Mackie; Chemicon, Millipore, Bedford, MA, USA; Abcam, Cambridge, MA, USA; MabTechnologies, Stone Mountain, GA,
USA; Sigma-Aldrich, St Louis, MO, USA.
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received an acute injection of WIN 55,212-2 at 0.3, 1.0, 3.0 or
7.0 mg ⁄ kg (n = 20) or vehicle (5% DMSO in saline, n = 5). Another
set of animals was divided into three treatment groups (acute, chronic
and chronic + abstinence). In the acute group, animals received one
injection of 3.0 mg ⁄ kg WIN 55,212-2 (n = 8) or vehicle (n = 6). The
chronic group received a daily injection of WIN 55,212-2 (n = 8) or
vehicle (n = 6) for 7 days. Animals in the dose–response study and in
the acute and chronic groups were killed 40–45 min after the last
injection. The chronic + abstinence group received repeated injections
(7 days) of WIN 55,212-2 (n = 8) or vehicle (n = 6) and were killed
7 days after the last injection. Experimental animals were anesthetized
with isoflurane (Isoflurane, USP; Webster Veterinary, Sterling, MA,
USA) and decapitated. Brains were removed and a coronal section
containing the whole extension of the Acb (from 0.7 to 2.7 mm
anterior to bregma) was cut. The area punched was located medially to
the anterior commissure and ventrally to the lateral ventricle, and
included the shell and medial core of the Acb (as shown in Fig. 2).
Part of the cerebellum was also collected from a coronal section from
10.50 to 12 mm posterior to bregma. Proteins were extracted in
radio immunoprecipitation assay lysis buffer (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA). Protein quantification was performed
using the bicinchoninic acid reagent. Protein samples were loaded at
equal concentrations and run on a 4–12% Tris-glycine gel (Invitrogen,
Carlsbad, CA, USA). Gels were then transferred to Immobilon-P
polyvinylidene difluoride membranes (Millipore Corp., Bedford, MA,
USA) at 25 V for 2 h. Membranes were probed for rabbit anti-a2A-
AR (1 : 500; Sigma-Aldrich), rabbit anti-b1-AR (1 : 1000; Sigma-
Aldrich) or mouse anti-NET (1 : 5000; MabTechnologies) using the
Western Breeze Chemilluminescent Kit (Invitrogen). In order to
control for protein loading, each blot was stripped using Restore
Stripping Buffer (Pierce, Rockford, IL, USA) and re-probed for
b-actin (1 : 5000; Sigma-Aldrich).
Light microscopy and immunofluorescence
Seven naı̈ve animals were used for light and immunofluorescence
microscopy. Animals were deeply anesthetized with sodium pento-
barbital (60 mg ⁄ kg), administered intraperitoneally, and transcardially
perfused with 50 mL of heparinized saline followed by 400 mL of 4%
formaldehyde (Electron Microscopy Sciences, Fort Washington, PA,
USA) in 0.1 m phosphate buffer (PB; pH 7.4). After perfusion, brains
were removed and postfixed in the same fixative. Coronal sections
throughout the Acb and the NTS were cut at 40 lm using a Vibratome
M
V
Fig. 1. Specificity of CB1R primary antibody. (A and C) Brightfield photomicrographs showing immunoperoxidase labeling for CB1R in a cross-section of (A) the
frontal cortex (FC) and (C) the Acb (arrows) of a wild-type mouse brain. (B and D) Immunohistochemistry for CB1R in equivalent cross-sections of a CB1R-
knockout mouse reveals an absence of immunolabeling in (B) the FC and (D) the Acb. Inset in C shows higher magnification of CB1R-labelled fiber indicated in C.
AC, anterior commissure; M, medial; V, ventral. Scale bar, 100 lm.
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(Technical Product International, St Louis, MO, USA) and collected
into 0.1 m PB. Every sixth section of the Acb was processed for
immunohistochemical visualization of calbindin, CB1R or DBH
immunoreactivities. Free-floating sections were treated with 1%
sodium borohydride in 0.1 m PB for 30 min. They were then rinsed
with 0.1 m PB and later washed in 0.1 m Tris saline buffer (TS; pH
7.6). The sections were blocked in 0.5% bovine serum albumin (BSA)
in 0.1 m TS for 30 min and then washed for 5 min, twice. Sections
were incubated overnight at room temperature with a mouse antibody
for calbindin (1:300; Abcam, Cambridge, MA, USA), a rabbit
antibody directed against CB1R (1:500) or a mouse monoclonal
antibody recognizing DBH (1:1000; Chemicon, Millipore) in 0.1%
BSA with 0.25% Triton-X 100 in 0.1 m TS. The sections were then
washed in 0.1 m TS, three times for 10 min. Then, sections were
incubated in a secondary biotin-conjugated donkey antirabbit or
donkey antimouse IgG (1 : 400; Jackson ImmunoResearch, West
Grove, PA, USA) in 0.1% BSAwith 0.25% Triton-X 100 in 0.1 m TS
for 30 min at room temperature. Then sections were washed in 0.1 m
TS, three times for 10 min. Sections were incubated in an avidin–
biotin complex solution (VECTASTAIN Elite ABC Kit; Vector
Laboratories, Burlingame, CA, USA) in 0.1 m TS for 30 min and then
washed. CB1R and DBH immunoreactivity was visualized with a red
reaction by incubating the tissue sections in a red peroxidase substrate
(VECTOR NovaRED substrate kit; Vector Laboratories) for 5 min,
while the calbindin immunoreactivity was visualized with a blue
reaction by incubating the sections in a blue peroxidase substrate
(VECTOR SG substrate kit) for 10 min. The reaction was stopped by
rinsing the sections in distilled water and then the sections were
washed in 0.1 m TS. For dual immunofluorescence, every sixth
section of Acb and NTS was processed as described above except that
tissues were incubated overnight in a cocktail with rabbit anti-CB1R
(1 : 500 for Acb sections, 1 : 5000 for NTS sections) and mouse anti-
DBH antibodies or rabbit anti-CB1R and mouse anti-MAP2 (1 : 1000;
Abcam) in 0.1% BSA+2% TritonX- 100 in 0.1 m TS. Tissue sections
were then incubated in a secondary antibody solution containing
fluorescein isothiocyanate donkey antimouse IgG (1 : 200; Jackson
ImmunoResearch) and tetramethyl rhodamine isothiocyanate antirab-
bit IgG (1 : 400; Jacskon ImmunoResearch) in 0.1% BSA+2% Triton-
X 100 in 0.1 m TS, for 2 h at room temperature. Sections were then
washed in 0.1 m PB. Both dual- and single-labeled sections were
mounted onto gelatinized glass slides from a 0.05 m PB solution. The
slides were dehydrated through a graded series of alcohols and cleared
in xylene before being coverslipped with Permount (light microscopy;
Fisher Scientific, Pittsburgh, PA, USA) or DPX (immunofluorescence;
Sigma-Aldrich) mounting mediums.
Electron microscopy
Although DBH was an adequate marker for noradrenergic terminals
using light and fluorescence microscopy because it was possible to
increase penetration with detergents in thicker tissue sections, this
vesicular-bound enzyme was more difficult to consistently detect
using electron microscopy with low concentrations of permeabiliza-
tion agents. Therefore, without using detergents, NET was used as a
marker to detect noradrenergic axon terminals and did not compromise
the ultrastructural preservation of the neuropil. NET and CB1R were
visualized in sections through the Acb obtained from naı̈ve rats
(n = 7) that were perfused with 50 mL of heparinized saline followed
by 100 mL 3.8% acrolein (Electron Microscopy Sciences) and
400 mL of 2% formaldehyde (Electron Microscopy Sciences) in
0.1 m PB. Sections were processed following the protocol described
for light microscopy except that Triton-X 100 was not added to the
solution for antibody incubation. The sections were incubated
overnight, at room temperature, in a primary antibody solution
containing rabbit anti-CB1R (1 : 500) and mouse anti-NET (1 : 1000)
with 0.1%BSA in 0.1 m TS. The NET antibody was visualized using
immunoperoxidase detection by incubating sections in biotinylated
donkey antimouse IgG (1 : 400; Jackson ImmunoResearch Laborato-
ries) followed by avidin–biotin complex (Vector Laboratories). The
sections were then reacted with 22 mg of 3-3¢ diaminobenzidine
(DAB; Sigma-Aldrich) containing 0.05% hydrogen peroxide for
15 min. For immunogold detection of CB1R, sections were then
incubated in ultrasmall gold-conjugated goat antirabbit IgG (1 : 50;
Electron Microscopy Sciences) with 0.8% BSA in 0.01 m PBS
containing 0.1% fish gelatin (Amerhsam Corp., Amerhsam, UK) for
2 h. Sections were rinsed in the same buffer and then rinsed in 0.01 m
PBS and incubated in 2% glutaraldehyde (Electron Microscopy
Sciences) in 0.01 m PBS for 10 min, followed by washes in 0.01 m
PBS and 0.2 m sodium citrate buffer (pH 7.4). A silver enhancement
kit (Amersham Corp.) was used for silver intensification of the gold
particles. Following intensification, tissue was rinsed in 0.1 m PB and
incubated in 2% osmium tetroxide in 0.1 m PB for 1 h, washed in
0.1 m PB, dehydrated and flat-embedded in Epon 812 (Electron
Microscopy Sciences). The reverse labeling was performed in which
Fig. 2. Representative photomicrographs of the region of the Acb excised for protein analysis. A coronal section, ranging from just rostral to the optic chiasm to
2 mm anterior, was obtained in order to include the entire rostrocaudal extent of the Acb. Bilateral punches of the Acb were performed using a trephine medially to
the anterior commissure (AC) and ventrally to the lateral ventricle (LV).
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CB1R was visualized by immunoperoxidase detection by using
biotinylated donkey antirabbit (1 : 400; Jackson ImmunoResearch
Laboratories) and immunogold detection of NET was visualized by
ultrasmall gold-conjugated goat antimouse IgG (1 : 50; Electron
Microscopy Sciences). Thin sections of 74 nm in thickness from the
mid-ventral shell of the Acb were cut using diamond knife and
collected on copper mesh grids.
Controls
For Western blot analysis, in order to minimize differences in the areas
excised for protein extraction, the same investigator conducted the
tissue dissection. To minimize protein loading errors, all gels run were
loaded by the same person.
For immunohistochemical experiments, to control for specificity of
the secondary antibodies, controls in which the primary antisera was
omitted were run in parallel. Sections processed in the absence of
primary antibody did not exhibit immunoreactivity. To evaluate cross-
reactivity of labeling of the primary antiserum by secondary antisera,
some sections were processed for dual labeling with omission of one
of the primary antisera. To assure that DBH and NET stained the same
profiles, dual immunofluorescence for DBH and NET was performed




Blots were scanned into a PC computer and band intensities were
quantified using Kodak Molecular Imaging Software (Version 4.5;
Carestream Health Inc., Rochester, NY, USA). Intensities of bands for
the adrenergic receptor proteins were normalized to that of b-actin in
the same sample. Average intensity of bands for acute control tissues
was arbitrarily set at 1. Statistical analysis was performed using spss
16.0 Graduate Student Version. Statistical analysis of data from the
dose–response study was conducted using a one-way anova followed
by post hoc Bonferroni (with significance set at P < 0.05). For the
analysis of the effects of acute, chronic and abstinence, a 2 · 3 anova
on the interaction between drug treatment (vehicle and drug) and
treatment duration (acute, chronic and abstinence) was conducted.
When a significant interaction was observed between the two factors,
simple effects tests were conducted and a Bonferronni correction was
applied. The results are expressed normalized to vehicle group values
and SEM values are given.
Light microscopy
Slides with single-labeled sections were visualized using a Leica
DMRBE microscope (Wetzlar, Germany), and images were acquired
using spot Advanced software (Diagnostics Instruments, Inc., Sterling
Heights, MI, USA). Figures were then assembled and adjusted for
brightness and contrast in Adobe Photoshop CS2. Schematics showing
the distribution of CB1R and DBH immunoreactivity are represented
on coronal diagrams (from 2.7 to 1.0 mm anterior to bregma) from the
rat brain atlas of Paxinos & Watson (1997) by direct visualization of
slides using a light microscope. Schematics were subsequently
assembled in Adobe Photoshop CS2.
Dual immunofluorescence
For immunofluorescence, sections were visualized using a confocal
microscope (Zeiss LSM 510 Meta; Carl Zeiss Inc., Thornwood, NY,
USA). Z-stacks from areas with dual labeling were collected and
analyzed; single optical planes were analyzed individually for
distribution and co-localization of the two markers throughout the
thickness of the section. The data presented represent projections of
six to nine single optical planes except for dual fluorescence in the
NTS and CB1R and MAP2 pictures, for which a single plane from
the z-stack is shown. Digital images were obtained and imported using
the LSM 5 image browser. Figures were assembled and adjusted for
brightness and contrast in Adobe Photoshop CS2.
Electron microscopy
For ultrastructural analysis, at least 15 grids containing four to eight
thin sections (74 nm of thickness) each were collected from at least
three plastic-embedded sections of the mid-ventral shell of the Acb
from each animal. Thin sections were viewed using a Morgagni 268
digital electron microscope (FEI Company, Hillsboro, OR, USA),
initially at low magnification to ensure that background labeling in the
neuropil, deemed spurious, was not commonly encountered, then at
higher magnification to verify adequate cellular morphology. For
quantification, electron micrographs from thin sections of three
animals that showed optimal preservation of ultrastructural morphol-
ogy were taken at different magnifications, usually at 11 000· and
then at 14 000· to 22 000· for better resolution of the structures
analyzed. Figures presented were assembled and adjusted for bright-
ness and contrast in Adobe Photoshop CS2. Selective gold–silver-
labeled profiles were identified by the presence of at least two gold
particles within a cellular compartment. The criterion of a minimum of
two gold particles as indicative of positive immunolabeling is based
on the fact that one gold particle could occasionally be found in
profiles known to lack CB1R or NET immunoreactivity, such as
myelin and blood vessels. Immunoperoxidase labeling was regarded
as positive when the electron-dense precipitate in individual profiles
was considerably greater than that seen in other morphologically
similar profiles in the neuropil. The cellular elements were identified
based on the description of Peters et al. (1991). Somata contained a
nucleus, Golgi apparatus and smooth endoplasmic reticulum. Proximal
dendrites contained endoplasmic reticulum, were postsynaptic to axon
terminals and were > 0.7 lm in diameter. A terminal was considered
to form a synapse if it showed a junctional complex, a restricted zone
of parallel membranes with slight enlargement of the intercellular
space and ⁄ or associated with postsynaptic thickening. Asymmetric
synapses were identified by thick postsynaptic densities (Gray’s type
I); in contrast, symmetric synapses had thin densities (Gray’s type II)
both pre- and postsynaptically. The term ‘undefined’ synaptic contact
was used to denote parallel membrane association of an axon terminal
plasma membrane juxtaposed to that of a dendrite or soma which
lacked recognizable membrane specializations in the plane of section
analyzed, and with no intervening glial processes. The term ‘appo-
sition’ is also used to denote close parallel membrane associations of
axon terminals with other axon terminals and ⁄ or dendrites which
lacked recognizable specializations but were otherwise not separated
by glial processes.
Results
WIN 55,212-2 altered the expression of adrenergic receptors
in the Acb
The influence of a cannabinoid agonist on adrenergic receptor
expression in the Acb was assessed by Western blot analysis of
protein extracts that were obtained from the Acb of animals that
received either an acute systemic injection of WIN 55,212-2, repeated
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systemic injections of WIN 55,212-2 or repeated systemic injections
of WIN 55,212-2 followed by a period of abstinence. The region
targeted for tissue dissection included the area medial to the anterior
commissure (shell and medial core). As reported by others (Rudoy &
Van Bockstaele, 2007), protein extracts indicative of a2A-AR could be
identified at 45 kDa while proteins indicative of b1-AR migrated to
65 kDa.
Several studies have reported that CB1R agonists have biphasic
effects on behavior according to the dose used, with lower doses
stimulating locomotion and higher doses inhibiting it (Rodriguez de
Fonseca et al., 1998; Drews et al., 2005). Cannabinoids have also
been shown to have anxiolytic and anxiogenic effects on animals
(Witkin et al., 2005). For the dose–response study, a one-way anova
demonstrated a significant difference among treatment groups in
b1-AR protein expression (P = 0.02; F3,12 = 10.833) and post hoc
comparison tests revealed that acute administration of WIN 55,212-2
induced a decrease in the expression of b1-AR at concentrations of 1.0
and 3.0 mg ⁄ kg (P < 0.05) when comparing to vehicle-treated animals
(Fig. 3A). Conversely, one-way anova revealed no significant
difference in a2A-AR protein expression (P = 0.271; F3,14 = 1.49),
demonstrating that none of the concentrations used had an effect on
a2A-AR protein levels in the Acb with an acute injection (Fig. 3A).
To investigate the effects of repeated administration of WIN 55,212-2,
the 3.0 mg ⁄ kg concentration was used as it has also been shown that
this concentration, but not 1.0 mg ⁄ kg, increases extracellular NE in
the PFC (Oropeza et al., 2005). In addition, 3.0 mg ⁄ kg has been
shown to induce c-fos expression in the NTS (Jelsing et al., 2009).
Worthy of note, the high dose used (7.0 mg ⁄ kg) had very pronounced
sedative effect on the animals, making this dose unsuitable for future
studies.
To assess the effects of repeated administration of WIN 55,212-2 in
a2A-AR and b1-AR protein expression a two-way anova on the
interaction between drug treatment (vehicle and drug) and treatment
duration (acute, chronic and abstinence) was conducted (Fig. 3B).
With respect to the effects in a2A-AR expression, the analysis
revealed a significant interaction between the two factors (P = 0.03,
F2,26 = 4.103). Therefore, a simple effects tests comparing vehicle-
and drug-treated animals were conducted for the acute, chronic and
abstinence conditions. A Bonferronni correction was applied. No
differences in a2A-AR expression were observed with an acute
injection of WIN 55,212-2 (3.0 mg ⁄ kg). However, the mean differ-
ence observed in the chronic condition (mean difference 0.42) was
significant (P < 0.01; t (5) = 7.09). Similar effects were observed for
the abstinence condition [mean difference 0.54; P < 0.001;
t (11) = 4.87]. This shows that repeated treatment with WIN 55,212-2
(3.0 mg ⁄ kg) for 7 days (chronic group) significantly decrease
the expression of a2A-AR and that this effect persisted over time as
a2A-AR expression levels remained below control levels in the
abstinence group. With respect to the effects in b1-AR protein
expression, the analysis revealed a significant effect of drug treatment
(P < 0.001; F1.32 = 15.32) and treatment duration (P < 0.001;
F2,32 = 10.67). The effect of treatment condition suggested that subjects
given WIN 55,212-2 showed a significantly decrease in b1-AR
expression comparing to vehicle-treated animals. However, no interac-
tion between the two factors was found (P = 0.353; F2,21 = 1.076).
Two-way anova revealed no significant interaction between a2A-
AR (P = 0.668; F2,16 = 0.414) and b1-AR (P = 0.29; F2,18 = 1.327)
protein expression in samples from the cerebellum, an area rich in
CB1R and noradrenergic input (data not shown). No significant effect
was observed with respect to NET expression after treatment with
WIN 55,212-2 (3.0 mg ⁄ kg; P = 0.466; F1,18 = 0.555; supporting
Fig. S5).
Topographic distribution of CB1R in Acb core and shell
subregions
The Acb extends for 2.2 mm in the ventral striatum and is composed
of a central ‘core’ and a peripheral and medially situated ‘shell’
subregion (Zahm, 1999; van Dongen et al., 2008). To adequately
distinguish the neuroanatomical boundaries of the core and shell
subregions within the Acb, calbindin immunoreactivity was used as a
marker to define these two subregions in adjacent coronal sections. As
previously reported (Jongen-Relo et al., 1994; Tan et al., 1999),
calbindin immunoreactivity was more prominent in the core and the
overlying striatum where it often appeared in cell bodies (Fig. 4B).
Our data are consistent with these reports, as calbindin immunoreac-
tivity appeared prominently in the Acb core where peroxidase-labeled
cell bodies could be identified immediately adjacent to the anterior
commissure and approaching the lateral ventricle dorsally. The
Fig. 3. Western blot for a2A and b1 adrenergic receptors (a2A- and b1-AR)
from the Acb following WIN 55,212-2 treatment. Bands shown are represen-
tative of one sample from one animal of each group. (A) Dose–response study
showing that acute administration of WIN 55,212-2 decreased the levels of b1-
AR in the Acb at 1.0 and 3.0 mg ⁄ kg (*P < 0.05). None of the doses used had
an effect on the levels of a2A-AR. (B) Western blot for a2A- and b1-AR in
protein extracts from the Acb of rats administered WIN 55,212-2 (3.0 mg ⁄ kg)
or vehicle, acutely (one injection) or chronically (7 days) and killed 40–45 min
or 7 days (Chr+Abst group) after the last injection. a2A-AR expression was not
altered by acute treatment with WIN 55,212-2. However, after chronic
treatment there was a significant (**P < 0.01) decrease in the expression of
a2A-AR and this decrease persisted in the absence of the drug for 7 days
(Chr+Abst group; ***P < 0.001). Two-way anova shows that b1-AR
expression was significantly reduced after treatment with WIN 55,212-2 when
compared to vehicle-treated animals. Data are presented as mean (+SEM) of
change in band intensity normalized to values for vehicle-treated animals, with
acute vehicle-treated animals set at 1.
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Fig. 4. (A) Diagram of a coronal section of rat forebrain adapted from the rat brain atlas of Paxinos & Watson (1997) showing subregions of the Acb in the ventral
striatum. The core subregion of the Acb surrounds the anterior commissure (AC) whereas the shell subregion is situated medial and ventral to the lateral ventricle
(LV). (B) Brightfield photomicrograph of calbindin immunoreactivity in a coronal section of rat brain at an equivalent level to that shown in panel (A). Calbindin
immunoreactivity is more intense in the core and dorsal striatum (dSt), with almost no labeling in the shell. (C and D) Brightfield photomicrographs, from the shell of
the Acb at 1.7 mm anterior to bregma, of CB1R and DBH-ir, respectively. High magnification of CB1R and DBH-ir shows tortuous and beaded (arrowheads)
processes. (E and F) Darkfield photomicrographs of CB1R immunoreactivity at two different levels of the Acb. CB1R-ir is seen (E) in the shell at mid-levels,
0.7 mm anterior to bregma and (F) in the core at more caudal levels (1.0 mm anterior to bregma). (F) At this level, CB1R immunoreactivity is almost completely
absent from the dorsal shell. (G and H) Darkfield photomicrographs showing DBH immunoreactivity at the same level as CB1R immunoreactivity in E and F,
respectively. (G) Some DBH immunoreactivity is seen at mid-levels of the shell and (H) intense DBH immunoreactivity is seen in the shell at caudal levels. M,
medial; V, ventral. Scale bar, 100 lm (B and E–H), 25 lm (C and D).
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distribution of calbindin immunoreactivity, along with the anterior
commissure and lateral ventricle, were used as references to identify
the level of Acb and its subregions when analyzing the distribution of
CB1R and DBH (Fig. 4A and B). The rostrocaudal segment of the
Acb was systematically categorized into three levels for the purpose of
the analysis: rostral (from 2.7 to 1.7 mm anterior to bregma), middle
(from 1.7 to 1.0 mm anterior to bregma) and caudal (from 1.0 to
0.6 mm anterior to bregma), coordinates according to the rat brain
atlas of Paxinos & Watson (1997).
Localization of CB1R in the Acb was consistent with previous
reports (Robbe et al., 2001; Pickel et al., 2004; Kearn et al., 2005).
Immunoperoxidase and immunofluorescence labeling of CB1R was
identified in long, beaded processes (Figs 4C, and 5A and B)
consistent with axonal profiles and punctate deposits that were more
consistent with a postsynaptic distribution (Fig. 5A). For simplicity,
only CB1R processes are represented on the schematic illustrations
(Fig. 6). CB1R-immunoreactive (-ir) processes were found throughout
the rostrocaudal extent of the Acb but with a differential distribution
within the shell and core subregions. CB1R-ir shifted from dorsal to
ventral aspects of the shell with caudal progression through the Acb.
However, in the caudal third division of the Acb, CB1R-ir was more
prominent within the Acb core subregion (up to +1.0 mm from
bregma), with little immunoreactivity in the shell (Fig. 4F). Clusters of
CB1R-ir processes were particularly evident in the mid-ventral shell
and in the core at caudal levels (Figs 4E and F, and 5B). CB1R
labeling was seen in long processes running either medially or
ventrally. Although not depicted on the schematic illustrations, CB1R
was also seen in profiles consistent with somatodendritic structures
(Fig. 5A) as reported by others (Pickel et al., 2004; Kearn et al., 2005;
Villares, 2007). To confirm the somatodendritic localization of CB1R
in this region, dual immunofluorescence of CB1R and the somato-
dendritic marker MAP2 showed double labeling, indicating that CB1R
was also present postsynaptically (Fig. 5E).
At the ultrastructral level, using the immunogold–silver detection
method, CB1R was identified both pre- (Fig. 7A) and postsynaptically
(Fig. 7B) in cellular profiles. Of 342 CB1R-ir cellular profiles
examined, 55% (189 ⁄ 342) were found in axon terminals and 45%
(153 ⁄ 342) in dendrites. Pickel et al. (2004) reported similar values:
59% in terminals and 41% in dendrites. Similar values were obtained
when CB1R was visualized using immunoperoxidase detection.
Immunocytochemical labeling for CB1R-ir was identified along the
plasma membrane of axon terminals as well as within the axoplasm
(Fig. 7). Axon terminals that exhibited CB1R-ir were unmyelinated
and contained synaptic vesicles that were heterogeneous in nature.
CB1R-ir dendrites contained mitochondria and endoplasmic reticulum
and were postsynaptic, mainly to unlabeled terminals. Of the axon
terminals exhibiting CB1R-ir, synaptic specializations were charac-
terized as symmetric or asymmetric. Semiquantitative analysis showed
that, out of 189 profiles counted, 17% (32 ⁄ 189) formed symmetric
synapses while 20% (37 ⁄ 189) formed asymmetric synapses (Fig. 7A).
The remaining profiles did not form sufficiently clearly recognizable
synaptic specializations in the plane of section analyzed to be
accurately classified.
Topographic distribution of DBH in Acb core and shell
subregions
Although distributed throughout the entire rostrocaudal extent of the
Acb, DBH-ir fibers also showed a topographic distribution (Fig. 4 and
6). DBH-ir was found in both the shell and core of the Acb except at
more caudal levels (+1.0 to +0.7 mm from bregma), where DBH-ir
was found mainly in the shell (Fig. 4H). This level corresponded to
the area of the Acb with the highest density of DBH-ir, where
abundant, beaded and tortuous DBH-ir fibers were seen. The density
of DBH-ir fibers decreased towards more rostral levels, with few fibers
being detected at the most rostral level (2.7 mm anterior to bregma).
Regions of high overlap between DBH-ir and CB1R-ir included the
ventromedial shell at mid-levels of the Acb (Fig. 6, panels 1.7 and
1.6 mm).
Ultrastructural analysis of noradrenergic terminals was also
assessed by electron microscopy. NET was used as a marker to detect
noradrenergic axon terminals and did not compromise the ultrastruc-
tural preservation of the neuropil. In order to assure that NET labeled
the same profiles as DBH, dual immunofluorescence was performed;
co-localization of the two markers in the same profiles occurred
(supporting Fig. S4). At the ultrastructural level, NET was detected
only in axon terminals. The peroxidase reaction resulted in a difuse
labeling within the terminals, with more intense labeling adjacent to
the plasma membrane (arrows in Fig. 7), while immunogold–silver
particles were found mainly in the cytoplasm, as reported by Miner
et al. (2003) in the PFC. Detection of NET with immunogold–silver
particles allowed better characterization of the synaptic specialization
of these axon terminals in 31% of the terminals analyzed (47 ⁄ 153).
NET was found to form mainly symmetric synapses (31 of 47; 66%),
in accordance with studies in the PFC (Miner et al., 2003), while
asymmetric synapses were found in 34% (16 ⁄ 47).
Immunofluorescence microscopy showed that CB1R and DBH
overlapped in both core and shell subregions of the Acb
Dual immunofluorescence for CB1R and DBH was conducted in the
same section of tissue to determine whether noradrenergic afferents
exhibit CB1R immunoreactivity. Both CB1R- and DBH immuno-
reactivity were found in beaded and tortuous processes (Fig. 5). The
beaded morphology was more evident within the DBH-ir fibers
(Fig. 5B and C). The distribution of CB1R- and DBH immunoreac-
tivity in the Acb was in concordance with the data obtained from
single labeling described above. Although CB1R immunoreactivity
was often found in areas containing noradrenergic fibers, rarely were
noradrenergic fibers positive for CB1R. However, in these areas of
overlap, CB1R- and DBH immunoreactivity appeared to converge on
common structures as the processes appeared to delineate cell bodies
of neurons in the Acb (double arrows in Fig. 5B), suggesting that
noradrenergic fibers and fibers containing CB1R may be converging
on common neurons.
Noradrenergic afferents to the shell of the Acb showed a low
frequency of co-existence with CB1R
The dual immunofluorescence data suggested multiple sites of
interaction between CB1R and noradrenergic afferents that could
only be fully resolved using ultrastructural analysis. The selection of
the mid-ventral shell of the Acb for EM analysis was based on the
light-microscopic data showing significant overlap in this area
(Fig. 6). NET was detected using immunoperoxidase while CB1R
was localized using immunogold–silver deposits (Fig. 7). In the area
sampled, CB1R and noradrenergic terminals were found to physically
interact in two ways. Some noradrenergic terminals were found to
have CB1R and some were found to be apposed to unlabeled profiles
containing CB1R. More specifically, 7.7% (9 ⁄ 113) of all NET-ir axon
terminals contained CB1R immunogold–silver particles, while 4.8%
(9 ⁄ 189) of all CB1R-containing axon terminals were found in NET-ir
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Fig. 5. Confocal fluorescence photomicrographs showing dual-labeling for CB1R and DBH in coronal sections of (A–C) the Acb and (D) the NTS, and (E) CB1R
and MAP2 in the Acb. CB1R was detected using a rhodamine isothiocyanate (red)-conjugated secondary antisera and DBH and MAP2 were detected using a
fluorescein isothiocyanate (green)-conjugated secondary antisera. Inset is a schematic diagram adapted from the rat brain atlas of Paxinos & Watson (1997) showing
the level (14.08 mm posterior to bregma) at which the photomicrograph was taken. (A–C) CB1R and DBH immunoreactivity are frequently seen in the same field
throughout the Acb. Both immunoreactivities show beaded processes resembling axonal structures (arrowheads in A) and punctate labeling consistent with
postsynaptic profiles (arrows in A). Some co-localization of the two markers (arrows in C) can be seen. In addition, independently labeled fibers appear to converge
on common structures (double arrows in B). (D) CB1R immunoreactivity is associated with DBH-labeled neurons (arrow) as well as unlabeled neurons (arrowhead)
in the NTS. Some of the DBH-labeled neurons lack CB1 immunoreactivity (double arrows). (E) Localization of CB1R in somatodendritic profiles labeled with
MAP2 (arrows). Scale bars, 20 lm.
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Fig. 6. Distribution of CB1R and DBH immunoreactivities along the extent of the Acb shown in schematics adapted from the rat brain atlas of Paxinos & Watson
(1997). Distances shown represent location anterior to bregma. CB1R immunoreactivity is depicted in schematics on the left while DBH immunoreactivity is shown
in schematics in the middle column. CB1R immunoreactivity was found diffusely in the core and in the shell subregions in the rostral third area of the Acb. At mid-
levels (1.7–1.0 mm), CB1R was found mainly in the shell and there was a rostrocaudal shift in CB1R immunoreactivity from the dorsal shell to the ventral shell. In
the caudal third of the Acb (up to 1.0 mm), CB1R immunoreactivity was found almost exclusively in the core. DBH immunoreactivity was found diffusely in the
shell and core subregions, with increased density as the nucleus progressed caudally. In the caudal third of the Acb (up to 1.0 mm), DBH immunoreactivity was very
intense in the shell and less so in the core. Trapezoids in the right column indicate the region sampled for ultrastructural analysis of CB1R and DBH distribution.
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axon terminals (Fig. 7F). With respect to the apposed labeling, 6.2%
(7 ⁄ 113) of all NET-ir axon terminals were apposed to profiles
containing CB1R immunogold–silver particles (Fig. 7D). Conversely,
1.6% of all CB1R-containing axon terminals were apposed to NET-ir
axon terminals, while 2.6% of all CB1R-containing dendrites were
apposed to NET-ir axon terminals. In regions of apposition, no
synaptic specialization of the CB1R-containing terminals was recog-
nizable in the cross-section analyzed.
CB1R were located in noradrenergic neurons in the NTS
As the cannabinoid agonist was administered systemically, the effects
of WIN 55,212-2 on the expression of AR in the Acb could also be
due to its actions on CB1R located in noradrenergic nuclei projecting
to the Acb, i.e. the NTS. To assess this, dual immunofluorescence for
CB1R and DBH was performed in tissue sections containing the NTS.
DBH immunoreactivity was found diffusely in cell bodies as well as in
processes resembling dendrites (Fig. 5D). CB1R immunoreactivity
exhibited a punctate distribution and co-localized in the cytoplasm of
noradrenergic neurons (positive for DBH) as well as non-noradren-
ergic neurons (lacking DBH-ir). Some of the DBH-labeled neurons
lacked CB1R-ir.
Discussion
The present study demonstrates that systemic administration of a
cannabinoid agonist alters the expression of ARs in a key limbic
forebrain region related to motivated behaviors. Light and ultrastruc-
tural microscopy studies indicate several potential cellular sites for
interaction between the two systems that include co-existence in
common axon terminals, serial modulation by convergence of
separately labeled axon terminals on common postsynaptic targets
and indirect effects on noradrenergic brainstem perikarya that provide
afferent input to the Acb.
Methodological considerations
The present study analyzed the expression of AR in the Acb following
treatment with WIN 55,212-2 or vehicle. The Acb can be divided into
core and shell subregions. At more rostral levels, the two regions can
be easily microdissected but at more caudal levels the core subregion
completely surrounds the anterior commissure while the shell
subregion surrounds it ventrally. To avoid dissecting the anterior
commissure we oriented our micropunches to target the Acb medial to
the anterior commissure, leaving out the core that sits lateral to it and
part of the ventrolateral shell from the dissection. As micropunches of
the Acb were used for the quantification of the ARs, the exact area
where these changes occurred (shell vs. core subregions, rostral vs.
caudal) cannot be established. Also, whether the changes observed are
due to a decrease in both pre- and postsynaptic receptors cannot be
defined.
A potential limitation known to be associated with the pre-
embedding immunolabeling technique is penetration of immuno-
reagents in thick Vibratome sections (Chan et al., 1990). To
circumvent this possibility, analysis of ultrathin sections was carried
out exclusively on sections near the tissue–plastic interface where
penetration is maximal. Limitations associated with the specificity of
immunogold labeling were overcome by quantifying only the profiles
containing two or more immunogold–silver particles. This may lead to
an underestimation of actual cellular relationships. However,
this approach minimized the reporting of potential spurious gold
labeling.
AR changes in the Acb following CB1R agonist treatment
To our knowledge, we are the first to report a change in adrenergic
receptor expression in the Acb following exposure to systemic
administration of the synthetic cannabinoid agonist WIN 55,212-2.
Our results demonstrate a decrease in b1- and a2A-AR protein
expression in the Acb following acute and ⁄ or chronic exposure.
A decrease in protein expression levels may be related to downregu-
lation of the receptor as adrenergic receptors, which belong to the
G protein-coupled receptor (GPCR) superfamily, are known to
desensitize, internalize and downregulate their expression following
binding of an agonist (Heck & Bylund, 1997; Dunigan et al., 2002).
Because desensitization does not seem to depend on protein degra-
dation (as removal of agonist rapidly restores receptor function; Hein
& Kobilka, 1995), no differences in total receptor protein would be
expected during desensitization. In contrast, downregulation of
Fig. 7. Electron photomicrographs from the Acb shell subregion showing
immunogold–silver labeling (arrowheads) for CB1R and immunoperoxidase
labeling for NET. Irrespective of whether the immunolabeling was in (A) an
axon terminal or (B) a dendrite, immunogold–silver particles for CB1R could
be detected within the cytoplasm as well as associated with the plasma
membrane. (A) Example of immunogold–silver labeling for CB1R in an axon
terminal (CB1R-t) forming an asymmetric, excitatory-type synapse (curved
arrow) with an unlabeled dendrite (ud). (B) CB1R immunolabeling is present in
a dendrite (CB1R-d) that receives a symmetric, inhibitory-type synapse (thin
arrow) from an unlabeled terminal (ut). (C) Dual localization of NET and CB1R
using immunoperoxidase detection for NET and gold–silver labeling for CB1R.
NET can be identified in an axon terminal by the presence of a diffuse
peroxidase precipitate with intense immunoreactivity along the plasma
membrane (thick black arrow). The immunoperoxidase-labeled NET axon
terminal (NET-t) is found in the same field as a CB1R-t that is labeled with
gold–silver particles (arrowheads). (D) A NET-t is apposed to a CB1R-t labeled
with immunogold–silver. (E) Example of reverse labeling using immunoper-
oxidase for CB1R which is apposed to an unlabeled dendrite (ud). (F) An
example of an axon terminal that exhibits labeling for both CB1R and NET
(CB1R + NET-t). (G) A NET-t exhibiting immunoperoxidase labeling and a
CB1R-t converging onto the same unlabeled dendrite (ud). Scale bars, 500 nm.
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GPCRs can be defined as a loss of total cellular binding activity or
decrease in receptor density (Barturen & Garcia-Sevilla, 1992; Hein &
Kobilka, 1995; Heck & Bylund, 1997). Mechanisms for downregu-
lation may include protein degradation, destabilization of the receptor
mRNA or repression of gene transcription.
We have previously reported that acute and chronic systemic
administration of WIN 55,212-2 is capable of increasing NE release
in the PFC with concomitant activation of c-fos activation in
brainstem noradrenergic neurons (Oropeza et al., 2005; Page et al.,
2007). In addition, others have shown that WIN 55,212-2
(3.0 mg ⁄ kg) is able to induce c-fos expression in the NTS (Jelsing
et al., 2009). It is tempting to speculate that the downregulation of AR
in the Acb following WIN 55,212-2 may occur due to an increase in
NE release in the Acb. The fact that NET expression in the Acb is not
affected by WIN 55,212-2 administration suggests that the reuptake
of NE by this transporter remains constant although binding tests
should be performed to confirm this. We have recently described a
decrease in b1-AR levels in the PFC after chronic treatment with
WIN 55,212-2, with no changes in the levels of a2A-AR (Reyes
et al., 2009). The distinct effect of WIN 55,212-2 on the levels of
ARs in the PFC and Acb may account for the anatomical and
functional differences between the two areas. Anatomically, the PFC
receives its noradrenergic input solely from the LC while the Acb is
innervated mainly by the NTS (Delfs et al., 1998; Olson et al., 2006).
The present study, therefore, by assessing noradrenergic afferents to
the Acb, provides information regarding the interaction of the
cannabinoid system with limbic-forebrain projections originating
specifically from the NTS. Also, the subcellular localization of the
AR in the Acb is not known but they are found to be both pre- and
postsynaptic in other brain regions such as the PFC (MacDonald
et al., 1997; Ramos & Arnsten, 2007; Wang et al., 2007). The
localization of AR with CB1R is being analyzed and, based
on previous studies showing preferential presynaptic localization of
a2-AR (Flugge et al., 2004), we hypothesize that axon terminals in
the Acb expressing a2-AR will be apposed to terminals containing
CB1R. Considering our localization of CB1R in dendrites and the
known association of b1-AR receptors with the postsynaptic density
protein in other brain regions (Strader et al., 1983; Aoki et al., 1987;
Hu et al., 2000), we also anticipate a potential co-localization of
b1-AR and CB1R postsynaptically. It has been proposed that
activation of CB1R can sequester G proteins, making them unavail-
able for other GPCRs such as a2-AR and somatostatin receptors
(Vasquez & Lewis, 1999). Whether disruption of this GPCR signaling
can ultimately lead to their downregulation has not been addressed
yet. Activation of CB1R is also known to lead to changes in
membrane potential and to alter the levels of intracellular cAMP
(Demuth & Molleman, 2006). cAMP can initiate intracellular
pathways that can lead to inhibition of AR synthesis or to
destabilization of AR mRNA, contributing to downregulation of the
receptor (Kirigiti et al., 2001; Dunigan et al., 2002). In addition,
stimulation of CB1R activates protein kinases that could participate in
the regulation of gene expression (Piomelli, 2003).
CB1R and DBH were topographically distributed within the Acb
Our data are in agreement with others’ with regard to the presence of
noradrenergic terminals and CB1R immunoreactivity in the Acb
(Berridge et al., 1997; Delfs et al., 1998; Tsou et al., 1998; Robbe
et al., 2001). However, the present study adds a detailed analysis of
the distribution of CB1R immunoreactivity not provided in these
studies. Robbe et al. (2001) identified CB1R immunoreactivity in
large, poorly branched fibers exhibiting intensely immunostained
varicosities that were localized mostly in the core subregion of the
Acb. We report the same type of immunostaining for CB1R but we
provide new data showing that CB1R is also found in the shell
subregion. Our analysis shows that CB1R immunoreactivity is not
uniform throughout the Acb. CB1R immunoreactivity is mainly found
in the core in the caudal third of the Acb and is found in the remaining
two-thirds of the nucleus in the shell subregion. Hence, CB1R
immunoreactivity seems to be more abundant in the shell. Careful
analysis by light microscopy of CB1R immunoreactivity in both the
core and the shell subregions did not reveal major differences in the
immunostaining pattern between the subregions, suggesting that
CB1R may function similarly in both the shell and core. The
distribution of DBH-ir in the Acb presented in this study is in
agreement with previous studies (Berridge et al., 1997; Delfs et al.,
1998). More specifically, DBH-ir was reported to be more evident in
the shell at caudal levels but it was also found at more rostral levels,
both in the shell and in the core.
In summary, our mapping of CB1R and DBH immunoreactivity in
the Acb shows an interesting topographic distribution of the two
markers. CB1R and DBH were shown to have an uneven
distribution throughout the nucleus. This fact may be relevant for
the anatomic and functional heterogeneity proposed for the Acb
(Zahm, 1999). Anatomical and behavioral studies support a rostro-
caudal gradient for appetitive vs. aversive behaviors (Reynolds &
Berridge, 2001, 2002, 2003). These studies suggest that the rostral
shell is important for appetitive ⁄ hedonic behaviors whereas the
caudal shell is important for aversive ⁄ fear behaviors, and that
GABAergic and glutamatergic transmission (through GABAA and
AMPA receptors) is involved. Modulation of GABAergic and
glutamatergic transmission in the intermediate shell produces com-
bined positive and negative motivational effects. Whether the
overlapping region of DBH and CB1R immunoreactivities described
in the present study correlates with these behaviors cannot be
established. However, our ultrastructural analysis of the middle third
of the shell subregion localized CB1R to terminals forming
symmetric (inhibitory) and asymmetric (excitatory) synapses, sug-
gesting that activation of CB1R can modulate inhibitory and
excitatory input in the Acb and therefore modulate behavior. In
addition, previous studies have shown that cannabinoids are able to
inhibit glutamate and GABA transmission in the Acb (Hoffman &
Lupica, 2001; Manzoni & Bockaert, 2001; Robbe et al., 2001;
Hoffman et al., 2003), mainly through a presynaptic mechanism.
Future studies should also address whether the presence of
noradrenergic fibers in this specific region is important for the
modulation of the abovementioned behaviors.
Subcellular localization of CB1R in the Acb
The CB1R subcellular distribution in the shell of the Acb analyzed in
the present study by electron microscopy is agreement with previous
studies but also shows some differences (Pickel et al., 2004; Matyas
et al., 2006). Discrepancies in anatomical studies may arise from
multiple factors. For example, the region of the Acb analyzed may
differ from study to study. As shown in the present study, the
distribution of both CB1R and noradrenergic fibers varies consider-
ably throughout the nucleus and sampling differences between
laboratories may lead to different results. In the present study, the
area selected for ultrastructural analysis was restricted to the
mid-ventral shell due to the higher incidence of overlap between
CB1R and DBH immunoreactivity observed by light and fluorescence
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microscopy. In addition, different criteria were used to quantify
profiles that exhibited CB1R immunoreactivity. In the present study,
only profiles containing two or more gold particles were included in
the semi-quantitative analysis whereas other groups (Pickel et al.,
2004) considered single immunogold–silver profiles as indicative of
positive labeling for CB1R. Finally, another difference relates to the
type of synapses formed by terminals containing CB1R. Matyas et al.
(2006) showed that all single-labeled CB1R-containing axon terminals
and dual-labeled CB1R and GABA axon terminals formed exclusively
symmetric synapses. On the other hand, Pickel et al. (2004) reported
that 42% of the CB1R-labeled axon terminals formed asymmetric
synapses while only 7% formed symmetric synapses. In the present
study, a similar number of terminals formed symmetric and asym-
metric synapses, although > 60% of the profiles exhibited synaptic
specifications that could not be unequivocally established in the plane
of section analyzed. Nevertheless, as mentioned before, cannabinoids
have been found to affect both glutamate and GABA transmission in
the Acb (Manzoni & Bockaert, 2001; Robbe et al., 2001). The
localization of CB1R in terminals forming symmetric and asymmetric
synapses in the present study is consistent with this.
As reported by Pickel et al. (2004), the present study shows
immunolabeling for CB1R in somatodendritc profiles in the Acb. This
is an interesting finding as cannabinoid actions are thought to be
mainly presynaptic. However, there is evidence for self-inhibition of
cortical interneurons by cannabinoids in an autocrine manner, whereby
cannabinoids are synthesized postsynaptically and activate nearby
CB1R (Piomelli, 2003; Bacci et al., 2004). Moreover, the fact that
fatty acid amide hydrolase (one of the enzymes responsible for
degradation of endocannabinoids) is located mainly in cell bodies and
dendrites (Egertova et al., 2003; Piomelli, 2003) may suggest that
cannabinoids might be able to act postsynaptically. Nevertheless,
whether CB1R located postsynaptically in the Acb are functional and
activating intracellular pathways was not investigated in the present
study and warrants further investigation.
Anatomical data show interaction between CB1R and DBH
Our anatomical data show multiple sites for interaction between the
cannabinoid and noradrenergic systems in the Acb and the NTS
(Fig. 8). CB1R was found in noradrenergic terminals, in unlabeled
terminals apposed to noradrenergic terminals and in dendrites in the
Acb as well as in noradrenergic and non-noradrenergic neurons of the
NTS (Fig. 8, panel 1). Based on our anatomical data, we proposed
four potential mechanisms by which WIN 55,212-2 is modulating
AR expression. WIN 55,212-2 may be modulating the levels of AR
directly by activating CB1R present in profiles that express AR
(dendrites or axon terminals; Fig. 8, panel 2). WIN 55,212-2 can also
act on CB1R present in noradrenergic terminals (Fig. 8, panel 2)
modulating the release of NE. Continued agonist activation of AR by
NE can lead to receptor downregulation (Hein & Kobilka, 1995; Heck
& Bylund, 1997). A third intra-accumbal mechanism may account for
modulation by WIN 55,212-2 of AR. The majority of CB1R was
found in unlabeled profiles. The nature of these profiles is unknown,
but activation of CB1R by WIN 55,212-2 may contribute to
modulation of these profiles’ transmission with consequent effects
on noradrenergic terminals and profiles containing AR (Fig. 8, panel
3). Ultimately, WIN 55,212-2 may be acting on CB1R present in the
NTS, increasing the noradrenergic input to the Acb (Fig. 8, panel 4).
In fact, WIN 55,212-2 administration has been shown to induce c-fos
activation in the NTS (Jelsing et al., 2009). However, whether this
Fig. 8. Possible sites for modulation of noradrenergic transmission in the Acb by cannabinoids. (Top left panel). Schematic of a saggital rat brain showing the
noradrenergic input to the Acb arising from the NTS. (1) The present study shows that, in the Acb, CB1R is found in noradrenergic terminals (NE-t), unlabeled
terminals (ut) and in dendrites. CB1R is also present in somatodendritic profiles of noradrenergic neurons and unlabeled neurons (un) in the NTS. Adrenergic
receptors (AR) can be found pre- and postsynaptically (MacDonald et al., 1997; Ramos & Arnsten, 2007; Wang et al., 2007). CB1R mRNA has been shown to be
present in the Acb (Hohmann & Herkenham, 2000; Hurley et al., 2003). We hypothesize that cannabinoids may modulate noradrenergic transmission in the shell of
the Acb as follows. (2) Directly, through activation of CB1R present on noradrenergic terminals or dendrites. Whether dendritic CB1Rs are functional requires
further studies. Nevertheless, if functionally active these receptors could influence adrenergic receptor expression. (3) Indirectly, through activation of CB1R in
terminals apposed to noradrenergic terminals. (4) Indirectly, through activation of CB1R in the NTS neurons that send projections to the Acb.
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neuronal activation increases NE release in the Acb remains to be
elucidated.
Functional implications
Convergent studies in the literature suggest that cannabinoids may
play a role in several neuropsychiatric disorders (Maldonado et al.,
2006; Leweke & Koethe, 2008; Moreira & Lutz, 2008) such as
depression or schizophrenia. Interestingly, the CB1R antagonist
rimonabant was withdrawn due to an unacceptably high incidence
of neuropsychiatric side effects (Nissen et al., 2008; Sanofi-Aventis),
while CB1R agonists have been shown to alleviate depressive-like
behaviors in animal models (Gobbi et al., 2005; Hill & Gorzalka,
2005b). Moreover, Gobbi et al. (2005) showed that increased levels of
anandamide evoked an increase in noradrenergic neuron activity in the
LC. This is supported by previous work from our laboratory, showing
that administration of a synthetic cannabinoid is able to activate the
LC with increased levels of NE in the PFC (Oropeza et al., 2005; Page
et al., 2007). The present study adds to these data, as the decrease in
a2A-AR expression may account for the assumed increase in NE in
the Acb, as a2A-AR seem to function as autoreceptors by inhibiting
NE release from the presynaptic terminal (Kable et al., 2000). In fact,
local administration of a2-AR agonists in the Acb has been shown to
reduce the efflux of NE measured by microdialysis, while adminis-
tration of antagonists of a2-AR increased the release of NE (Aono
et al., 2007). Moreover, downregulation of b1-AR can be seen as a
mechanism which is adaptive to an increase in synaptic NE. Although
activation of a2-AR can decrease dopamine release in other brain
regions such as the PFC and hippocampus (Guiard et al., 2008;
Jentsch et al., 2008) this does not seem to be the case in the Acb.
Ihalainen and colleagues have shown that administration of an a2-AR
agonist would decrease dopamine in the Acb when administered
systemically but not when it was locally administered (Ihalainen &
Tanila, 2004). This supports the idea that a2-AR may be localized
mainly in noradrenergic terminals in the Acb. Therefore, the impact of
chronic WIN 55,212-2 on a2-AR levels in the Acb seems to be
selective for noradrenergic terminals. As NE is an important target for
the treatment of depression (Heninger et al., 1996; Nutt, 2002), it is
tempting to speculate that cannabinoids may impact mood- and
motivation-related behaviors by activating limbic forebrain noradren-
ergic circuits.
Supporting Information
Additional supporting information may be found in the online version
of this article:
Fig. S1. Specificity of the secondary antibody.
Fig. S2. Specificity of NET primary antibody.
Fig. S3. Specificity of b1-AR and a2A-AR antibodies.
Fig. S4. Confocal fluorescence photomicrographs showing dual-
labeling for NET and DBH in coronal sections of the Acb. NET and
DBH are co-localized to the same profiles.
Fig. S5. Results of western blot analysis for NET in the Acb showing
that treatment with WIN 55,212-2 (3.0 mg ⁄ kg) does not affect NET
expression.
Please note: As a service to our authors and readers, this journal
provides supporting information supplied by the authors. Such
materials are peer-reviewed and may be re-organized for online
delivery, but are not copy-edited or typeset by Wiley-Blackwell.
Technical support issues arising from supporting information (other
than missing files) should be addressed to the authors.
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